pargyline has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| Andringa, G | 1 |
| Cools, AR | 1 |
2 other studies available for pargyline and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca mulatta; Male; Neur | 2000 |